ArticleInternational ophthalmology2025
Refractive lenticule-assisted accelerated corneal cross-linking: a three-year clinical observation in patients with thin keratoconus.
Article in International ophthalmology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveAccelerated corneal cross-linking (A-CXL) is unsuitable for the treatment of thin keratoconus. We developed a technique termed Refractive Lenticule-assisted Accelerated Corneal Cross-Linking (RLA-ACXL) by overlaying lenticules during A-CXL to optimize therapy for thin keratoconus. This retrospective study evaluates the 3-year efficacy and safety of RLA-ACXL.
methodsThis study retrospectively included 63 eyes (from 42 patients) with progressive keratoconus who underwent A-CXL in our hospital from September 2017 to December 2020. The surgical method was determined based on corneal thickness. Patients who received RLA-ACXL (10 patients with 18 eyes) were designated as Group A, while those who underwent A-CXL alone (32 patients with 45 eyes) were classified as Group B. Both groups were followed for 3 years. Preoperative and postoperative evaluation (conducted at 6, 12, 24, and 36 months) included best corrected visual acuity (BCVA), endothelial cell density (ECD), thinnest corneal thickness (TCT), keratoconus vertex back (Kvb), and corneal curvature. Any adverse events occurring during follow-up, such as delayed corneal healing, infection, or haze, were recorded.
resultsThroughout the follow-up period, no significant changes were observed in TCT, Kmax, K1, K2, or Kvb in Group A. However, BCVA improved significantly by 36 months postoperatively (P < 0.05), and ECD showed a significant increase at the 12-month mark (P < 0.05). In the same period, Group B showed decreases in TCT and ECD compared to baseline (P < 0.05), along with increases in anterior surface K1 and K2 values, and improvements in BCVA and Kmax (P < 0.05). No significant change in Kvb was observed. Both groups exhibited uneventful healing with no adverse events. Notably, during the 12-month postoperative period, Group A exhibited more significant thickening of Kvb, greater decreases in TCT and K1, and more pronounced ECD recovery compared to Group B. During the 36-month follow-up, Group A exhibited more substantial improvements in BCVA and a more pronounced elevation in Kvb.
conclusionsOver the 3-year follow-up period, RLA-ACXL and A-CXL showed similar efficacy and safety in controlling the progression of keratoconus.
Indexed as
Identifiers
41385122What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.